The Neuromuscular Disease Network for Canada

funder-logos_nmd4c

Kathryn Selby

person-kathy-selby

Investigator

Clinical Assistant Professor, Pediatric Neurologist, Department of Pediatrics, Faculty of Medicine, University of British Columbia

Medical Director, Pediatric Neuromuscular Program of BC and the Yukon. Investigator at BC Children’s Hospital Research Institute


NMD4C Working Group(s): Expert Patient Capacity Building, Knowledge Translation

Email Kathryn

Biography

Dr. Kathryn Selby is a pediatric neurologist who is involved in acute and chronic clinical care as well as academic and research commitments in neurological and neuromuscular disorders.

Dr. Selby trained in St. Andrews and Manchester Universities in the UK and subsequently at the University of British Columbia and is the medical director of the pediatric neuromuscular program of British Columbia and the Yukon.

Her main areas of specialist interest are pediatric neuromuscular disorders including spinal muscular atrophy and Duchenne muscular dystrophy and she is involved with neurogenetics and knowledge translation. She plays an active role in medical education and was the former program director for the pediatric neurology program at UBC.

She has also partnered with Doctors of BC and has been involved in the development of long-term care plans for muscle specific disorders in the challenging area of transition of care from pediatric to adult care in children with complex neurological and neuromuscular disorders.
She is actively involved with clinical trials in neuromuscular disorders and in patient advocacy.

In the NMD4C network Dr. Selby is involved with developing and updating of clinical care guidelines and working with the team for implementation and dissemination and piloting of these guidelines. She is also developing a patient advocacy training module and will support knowledge translation within the neuromuscular community.

Recent publications

Chin, HL, Huynh, S, Ashkani, J, Castaldo, M, Dixon, K, Selby, K et al.. An infant with congenital respiratory insufficiency and diaphragmatic paralysis: A novel BICD2 phenotype?. Am J Med Genet A. 2021. PMID:34825470

Cook, CB, Armstrong, L, Boerkoel, CF, Clarke, LA, du Souich, C, Demos, MK et al.. Somatic mosaicism detected by genome-wide sequencing in 500 parent-child trios with suspected genetic disease: clinical and genetic counseling implications. Cold Spring Harb Mol Case Stud. 2021.7 (6) PMID:34697084

Shieh, PB, Elfring, G, Trifillis, P, Santos, C, Peltz, SW, Parsons, JA et al.. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res. 2021.10 (18)1337-1347 PMID:34693725

Woof, AL, Selby, K, Harris, SR. Ankle contractures and functional motor decline in Duchenne muscular dystrophy. Brain Dev. 2022.44 (2)105-113 PMID:34629214

Oskoui, M, Gonorazky, H, McMillan, HJ, Dowling, JJ, Amin, R, Gagnon, C et al.. Guidance on Gene Replacement Therapy in Spinal Muscular Atrophy: A Canadian Perspective. Can J Neurol Sci. 2021. 1-4 PMID:34082851

See more on PubMed